JJ
J&J shares plummet after asbestos cover up allegations emerge
December 17, 2018Sales and Marketing J&J, JJ, Johnson & Johnson, asbestos, reuters
Shares in American healthcare firm Johnson & Johnson plummeted on Friday after news agency Reuters reported that the New Jersey-based …
GSK retain top spot on access to medicines list
November 22, 2018Business Services, Research and Development GSK, J&J, JJ, R&D, Sanofi, access, low and middle income countries, researh
The majority (63%) of research and development projects are being conducted by just five companies; GSK, Johnson & Johnson, Sanofi, …
J&J buy global rights to Yuhan’s lazertinib in deal worth $1.2bn
November 6, 2018Manufacturing and Production J&J, JJ, NSCLC, Yuhan, deal, lazertinib, south korea
Johnson & Johnson’s Janssen Biotech unit has bought the rights to Yuhan’s third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib in a deal …
Top Ten most popular articles on Pharmafile.com this week!
November 2, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, GSK, ITH Pharma, J&J, JJ, NICE, Sanofi, Trump, top 10
Deals dominated the headlines this week as both Sanofi and AstraZeneca made billion dollar agreements. Meanwhile, the FDA gave magic …
J&J’s Invokana becomes first FDA-approved oral diabetes drug to reduce cardiovascular event risk
October 31, 2018Research and Development, Sales and Marketing FDA, J&J, JJ, invokana, pharma
The FDA has given the go-ahead for Johnson & Johnson’s drug Invokana (canagliflozin) for use in the risk reduction of …
US court overturns J&J’s Zytiga patent in combination with prednisone
October 29, 2018Sales and Marketing J&J, JJ, Johnson and Johnson, Zytiga, court, generic, prednisone
A court in New Jersey has invalidated Johnson & Johnson’s patent on the prostate cancer drug Zytiga when used in …
Top Ten most popular articles on Pharmafile.com this week!
October 26, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, GSK, HDA, J&J, JJ, brexit, clinical trials, pharmafile, resutls, stockpiling, top 10
Winter is coming! And with it an assortment of promising and not so promising results from big pharma. While J&J …
J&J announce promising Phase 1/2a results for HIV vaccine
October 23, 2018Manufacturing and Production AIDS, HIV, J&J, JJ, Vaccine, infectious diseases
The world may be one step closer to discovering a preventative vaccine for HIV following American multinational Johnson & Johnson’s …
GSK named third best UK workplace
October 22, 2018Sales and Marketing AbbVie, Amgen, BMS, Eli Lilly, GSK, J&J, JJ, work
British multinational GlaxoSmithKline has been rated as the third best company to work for in the UK, according to jobs …
J&J pledges to end global TB pandemic
September 25, 2018Manufacturing and Production J&J, JJ, Johnson and Johnson, TB, access, tuberculosis
Johnson and Johnson have announced that they are launching a 10-year initiative aimed at helping to end tuberculosis, the world’s …
Europe approves Janssen’s Darzalex in frontline multiple myeloma
September 4, 2018Manufacturing and Production, Research and Development, Sales and Marketing EU, Europe, J&J, JJ, Janssen, darzalex, multiple myeloma, pharma
Janssen has revealed that its CD38-targeting biologic drug Darzalex (daratumumab) has received approval from the European Commission, authorising its use …
The September 2018 issue of Pharmafocus is available to read online now!
September 3, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, AstraZeneca, Cancer, Iraw, J&J, JJ, Pfizer, Roche, UK, brexit, drug safety, pharma, pharmacovigilance
The new September edition of Pharmafocus is now live and available to read online. We’re entering the final stretch as …
NHS scraps restriction on availability of J&J’s Imbruvica in leukaemia patients
August 10, 2018Medical Communications, Sales and Marketing Cancer, J&J, JJ, Johnson & Johnson, NHS, NICE, UK, imbruvica, leukaemia, pharma
The NHS has dropped a controversial restriction preventing leukaemia patients from accessing Johnson & Johnson’s tyrosine kinase inhibitor Imbruvica (ibrutinib), …
Lawsuit alleges pharma giants funded terror in Iraq
August 2, 2018Business Services, Medical Communications, Sales and Marketing AstraZeneca, Iraq War, J&J, JJ, Litigation, Roche, corruption, terrorism
The United States Justice Department is investigating claims that major pharmaceutical and medical device companies were aware that supplies that …
Top Ten most popular articles on Pharmafile.com this week
July 27, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, China, GSK, Gilead, J&J, JJ, Pfizer, Remicade, Roche, antimicrobial resistance, biosimilar, pharma, pricing, viagra
With the UK in the grip of a record-breaking heatwave, it’s hard to focus on much else over here, but …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
Long-acting therapies set to reshape HIV treatment market
